Literature DB >> 30068283

A Review on Leukemia and iPSC Technology: Application in Novel Treatment and Future.

Amirhosein Maali1, Amir Atashi2, Sasan Ghaffari3, Reza Kouchaki4, Fereshteh Abdolmaleki4, Mehdi Azad4.   

Abstract

Leukemia is an uncontrollable growth of hematopoietic cells due to a mutation in DNA followed by cellular dysregulation and one or more chromosomal disorder that generally leads to a clonal abnormality. Theoretical and technical inability in early screening and distinguishing cancer, tumor tolerance to common treatment methods, repeated relapses of cancer after remission phase, heterogeneous chromosomal abnormality, and the side effects of current chemotherapies are some of challenges that we face with leukemia and other malignancies. Induced pluripotent stem cells (iPSC) opened a promising window to a wide range of diseases, including leukemia. Overcoming the barriers in leukemia is possible with iPSC technology. Induced hematopoietic stem cell transplantation (and gene therapy), induced cytotoxic T-lymphocytes and reprogrammed NK cells that strengthen the immune system, miRNAs, modeling approaches, and supportive cares are some aspects of the novel treatment based on iPSC technology. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Leukemia; gene therapy; iHSC; iPSC; malignancy modeling; miRNAs; reprogrammed NK cells; treatment.

Mesh:

Year:  2018        PMID: 30068283     DOI: 10.2174/1574888X13666180731155038

Source DB:  PubMed          Journal:  Curr Stem Cell Res Ther        ISSN: 1574-888X            Impact factor:   3.828


  4 in total

1.  The Gene Expression Profile and DNA Methylation Pattern of CDH1 and DNMT1 Genes in Acute Promyelocytic Leukemia (APL).

Authors:  Sanaz Zebardast; Mehdi Sahmani; Saeed Mohammadi; Farshad Foroughi; Ali Dehghani Fard; Zahra Mohammadi; Sahar Khojastepour; Mehdi Azad
Journal:  Rep Biochem Mol Biol       Date:  2020-01

2.  The Antihelminthic Drug, Mebendazole, Induces Apoptosis in Adult T-Cell Leukemia/Lymphoma Cancer Cells: In-Vitro Trial.

Authors:  Amirhosein Maali; Elaheh Ferdosi-Shahandashti; Farzin Sadeghi; Ehsan Aali
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2020-10-01

Review 3.  Hypoxia in Cell Reprogramming and the Epigenetic Regulations.

Authors:  Nariaki Nakamura; Xiaobing Shi; Radbod Darabi; Yong Li
Journal:  Front Cell Dev Biol       Date:  2021-01-28

Review 4.  Engineered NK Cells Against Cancer and Their Potential Applications Beyond.

Authors:  Maria Karvouni; Marcos Vidal-Manrique; Andreas Lundqvist; Evren Alici
Journal:  Front Immunol       Date:  2022-02-15       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.